Bedtime aspirin may reduce risk of morning heart attack

(Press-News.org) Contact information: Karen Astle
karen.astle@heart.org
214-706-1392
American Heart Association
Bedtime aspirin may reduce risk of morning heart attack Abstract 19559 (Clinical Science: Special Reports III -- Ballrooms C1&C2) Taking aspirin at bedtime instead of in the morning might reduce acute heart events, according a new study presented at the American Heart Association's Scientific Sessions 2013. Low-dose daily aspirin is recommended for people at high risk of heart disease and for reducing the risk of recurrent heart events. Aspirin thins the blood and makes it less likely to clot. The tendency for platelet activity to be higher peaks in the morning. The Aspirin in Reduction of Tension II trial is the first study to explore the timing of aspirin intake among cardiovascular disease patients. In the randomized, open-label study, 290 patients took either 100 mg of aspirin upon waking or at bedtime during two 3-month periods. At the end of each period, blood pressure and platelet activity was measured. Blood pressure was not reduced; however, bedtime aspirin platelet activity was reduced by 22 units (aspirin reaction units). "Because higher platelet activity contributes to a higher risk of acute heart events, this simple intervention – switching aspirin intake from morning to bedtime – could be beneficial for the millions of patients with heart disease who take aspirin on a daily basis," said Tobias Bonten, M.D., Ph.D student at the Leiden University Medical Center in the Netherlands. ### Note: Actual presentation is 3:45 p.m. CT/4:45p.m. ET Tuesday, Nov. 19, 2013.

For more news from AHA Scientific Sessions 2013 follow us on Twitter @HeartNews #AHA13.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

Additional resources related to these tips are on the right column of the release link at http://newsroom.heart.org/news/tuesday-news-tips?preview=b2873852502cdfc35fa2339bd73262ee. NOTE: ALL TIMES ARE CENTRAL. ALL TIPS ARE EMBARGOED UNTIL THE TIME OF PRESENTATION OR 3 P.M. CT/4 PM ET EACH DAY, WHICHEVER COMES FIRST. For more information Nov. 16-20, call the AHA News Media Staff Office in the Dallas Convention Center at (214) 853-8008. Before or after these dates, call the Communications Office in Dallas at (214) 706-1173. For public inquiries, call (800) AHA-USA1 (242-8721).